Bristol-Myers Squibb Overview

  • Founded
  • 1887

Founded
  • Status
  • Public

  • Employees
  • 32,200

Employees
  • Stock Symbol
  • BMY

Stock Symbol
  • Investments
  • 106

  • Share Price
  • $74.45

  • (As of Friday Closing)

Bristol-Myers Squibb General Information

Description

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.

Contact Information

Website
www.bms.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Biotechnology
Stock Exchange
NYS
Primary Office
  • 430 East 29th Street
  • 14th Floor
  • New York, NY 10016
  • United States

Bristol-Myers Squibb Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bristol-Myers Squibb Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$74.45 $72.77 $62.90 - $81.44 $155B 2.13B 9M $2.97

Bristol-Myers Squibb Financials Summary

In Thousands,
USD
TTM 31-Dec-2022 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020
EV 184,123,237 184,123,237 168,486,862 164,770,387
Revenue 46,159,000 46,159,000 46,385,000 42,518,000
EBITDA 18,540,000 18,540,000 20,191,000 5,035,000
Net Income 6,327,000 6,327,000 6,994,000 (9,015,000)
Total Assets 109,314,000 118,481,000
Total Debt 0 0 45,596,000 51,673,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bristol-Myers Squibb Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bristol-Myers Squibb‘s full profile, request access.

Request a free trial

Bristol-Myers Squibb Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cance
Drug Discovery
New York, NY
32,200 As of 2021
00000
00000000000 00000

000000

ercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000000000000
Cambridge, MA
0000 As of 0000
000.00
000 0000-00-00
000000&0

000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Bristol-Myers Squibb Competitors (11)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biogen Formerly VC-backed Cambridge, MA 0000 000.00 000000&0
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
000000 Corporation Durham, NC 00 000.00 000000000 000.00
0000000 0000000000 Formerly VC-backed Redwood City, CA 000 00000 000000000 00000
000000 Corporation Paris, France 00000 000000000000
You’re viewing 5 of 11 competitors. Get the full list »

Bristol-Myers Squibb Patents

Bristol-Myers Squibb Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2022033757-A Compositions and methods for treating tauopathies Inactive 10-Nov-2021
US-20220388987-A1 Substituted heterocyclic compounds Pending 14-May-2021 0000000000
US-20220411384-A1 Substituted heterocyclic compounds Pending 14-May-2021 0000000000
US-20220362255-A1 Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione Pending 21-Apr-2021 00000000000
US-20220324840-A1 Pyridinyl substituted oxoisoindoline compounds Pending 06-Apr-2021 C07D401/14
To view Bristol-Myers Squibb’s complete patent history, request access »

Bristol-Myers Squibb Executive Team (64)

Name Title Board Seat Contact Info
Giovanni Caforio MD Chairman & Chief Executive Officer
Louis Schmukler Executive Vice President & President, Global Product Development & Supply
David Elkins Executive Vice President & Chief Financial Officer
Gregory Meyers Executive Vice President & Chief Digital & Technology Officer
Cari Gallman JD Senior Vice President, Chief Compliance and Ethics Officer
You’re viewing 5 of 64 executive team members. Get the full list »

Bristol-Myers Squibb Board Members (20)

Name Representing Role Since
000000 0000 Self Board Member 000 0000
000000 000000 00 Self Board Member 000 0000
00000000 0000000 0 Bristol-Myers Squibb Chairman & Chief Executive Officer 000 0000
00000 000000 00 Self Board Member 000 0000
00000 0000000 00.0 Bristol-Myers Squibb Board Member, Senior Group Leader, The Francis Crick Institute and Chief Scientist, Cancer Research UK 000 0000
You’re viewing 5 of 20 board members. Get the full list »

Bristol-Myers Squibb Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bristol-Myers Squibb Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bristol-Myers Squibb‘s full profile, request access.

Request a free trial

Bristol-Myers Squibb Investments & Acquisitions (106)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 26-Jan-2023 00000 0000 000.00 Discovery Tools (Healthcare)
00000000 000 05-Jan-2023 000000000 0000 Buildings and Property
0000000000 20-Dec-2022 00000 0000 00000 Drug Discovery
00000 0000000 29-Nov-2022 00000 0000 000.00 Drug Discovery
SyntheX 04-Oct-2022 Later Stage VC Drug Discovery
You’re viewing 5 of 106 investments and acquisitions. Get the full list »

Bristol-Myers Squibb Subsidiaries (8)

Company Name Industry Location Founded
IFM Therapeutics Drug Discovery Boston, MA 2015
0000000 00000 0000 Drug Discovery San Diego, CA 0000
000000000 Drug Discovery Brisbane, CA 0000
0000000 Biotechnology Austin, TX 0000
0000000-00000 0000 Foundation New York, NY 0000
You’re viewing 5 of 8 subsidiaries. Get the full list »

Bristol-Myers Squibb ESG

Risk Overview

Risk Rating

Updated August, 13, 2022

22.73 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 15,638

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 1,008

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 465

Rank

0.0

Percentile

To view Bristol-Myers Squibb’s complete esg history, request access »

Bristol-Myers Squibb Exits (30)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000000 20-Jun-2021 00000 00000 00 00000 Completed
  • 14 buyers
0000000000 03-Mar-2021 00000 00000 00 00000 Completed
  • 5 buyers
00000 00000000 05-Jan-2021 00000 00000 00 00000 Completed
  • 12 buyers
000000 00000000000 29-May-2020 00000 00000 00 0000 Completed
  • 2 buyers
Silverback Therapeutics 11-Mar-2020 Early Stage VC 000.00 Completed
  • 9 buyers
You’re viewing 5 of 30 exits. Get the full list »